EV-associated non-coding RNAs in paediatric asthma airway remodelling: current mechanistic evidence and therapeutic

Yaling Liu1,2, Dan Wang1,2, Hu Gao1,2

  • 1WCSUH-Tianfu ⋅ Sichuan Provincial Children's Hospital, Meishan, Sichuan, China.

Insights

Extracellular vesicles (EVs) carrying non-coding RNAs are implicated in paediatric asthma airway remodelling. Research highlights microRNAs (miRNAs) but needs more data on long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in this process.

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Genetics

Background:

  • Paediatric asthma involves chronic airway inflammation and remodelling, leading to significant respiratory distress.
  • Airway remodelling encompasses epithelial injury, fibrosis, and smooth muscle proliferation, contributing to refractory asthma.
  • Non-coding RNAs (ncRNAs) like miRNAs, lncRNAs, and circRNAs regulate gene expression and are crucial in disease processes.

Purpose of the Study:

  • To review current evidence on extracellular vesicle (EV)-associated non-coding RNAs in paediatric asthma airway remodelling.
  • To assess the mechanistic evidence, translational relevance, and knowledge gaps regarding these molecules.
  • To clarify the role of ncRNAs carried by EVs in the pathogenesis of paediatric asthma.

Main Methods:

  • Narrative review of existing literature on EV-associated ncRNAs in paediatric asthma.
  • Analysis of studies focusing on microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs).
  • Evaluation of evidence regarding EV terminology and biogenesis, distinguishing operational terms from specific types like exosomes.

Main Results:

  • EVs are key mediators of intercellular communication, carrying ncRNAs that influence asthma pathophysiology.
  • Mechanistic evidence is most robust for miRNA involvement in paediatric asthma airway remodelling.
  • Evidence for EV-associated lncRNAs and circRNAs in this context is currently limited, with most studies using general EV terminology.

Conclusions:

  • EV-associated ncRNAs, particularly miRNAs, represent potential diagnostic biomarkers and therapeutic targets for paediatric asthma.
  • Further research is needed to elucidate the specific roles of EV-associated lncRNAs and circRNAs in airway remodelling.
  • Standardized methodologies for EV characterization are essential for advancing the field.

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...